Innovating Works

COGENTECH SOCIETA BENEFIT SRL

Desconocido
METABALANCANCER: Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy CONSORTIUM FOR GENOMIC TECHNOLOGIESSOCIETA BENEFIT SRL participó en un HORIZON EUROPE: ERC-2023-STG The goal of this proposal is to explore combinations of targeted metabolite supplementation and global nutrient restriction as a new strateg...
2023-11-17 - 2028-11-30 | Financiado
Sagittarius: A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE S... CONSORTIUM FOR GENOMIC TECHNOLOGIESSOCIETA BENEFIT SRL participó en un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 SAGITTARIUS aim to optimize the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC). Approximately half of...
2023-04-27 - 2028-06-30 | Financiado
TARGET: Targeting DNA repair pathways sparking anti cancer immunity CONSORTIUM FOR GENOMIC TECHNOLOGIESSOCIETA BENEFIT SRL participó en un H2020: ERC-2020-ADG This project will test for the first time the hypothesis that therapeutic inactivation of DNA repair pathways in cancer cells can be exploit...
2021-07-05 - 2026-09-30 | Financiado
diaRNAgnosis: A novel platform for the direct profiling of circulating cell free ribonucleic acids in biofluids CONSORTIUM FOR GENOMIC TECHNOLOGIESSOCIETA BENEFIT SRL participó en un H2020: H2020-MSCA-RISE-2020 Circulating cell-free ribonucleic acids (ccfRNAs) represent an emerging and important class of molecules, able to provide significant clinic...
2020-10-02 - 2025-05-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.